AYA.AX stock opens pre-market at A$3.10 on 06 Mar 2026 as investors weigh Artrya Limited’s AI diagnostic rollout against mixed financials. We focus on how Salix adoption, cash per share A$0.61, and a volatile volume profile are connecting to the share price. This piece uses ASX-listed data, recent Reuters and StockAnalysis coverage, and Meyka AI modelling to frame short and medium-term scenarios for AYA.AX stock.

AYA.AX stock price snapshot and immediate drivers

Artrya (AYA.AX) trades at A$3.10, with a day range A$3.05–A$3.16 and volume 179,764 versus average volume 620,518. Key public drivers today include routine Reuters financial data updates and ongoing product commercialisation progress visible on company profiles Reuters and StockAnalysis.

AYA.AX stock: business model, sector position and catalysts

Artrya Limited (AYA.AX, ASX) sells Salix, an AI cloud service for automated coronary artery disease detection, positioning it in Healthcare software and diagnostics. The broader Healthcare sector on ASX shows weaker YTD performance, which may pressure short-term sentiment even as adoption provides medium-term revenue levers.

AYA.AX stock financials and valuation metrics

At A$3.10 the market capitalisation is A$343,676,000 with EPS -0.17 and PE -17.76, reflecting losses during scale-up. Balance and liquidity metrics show cash per share A$0.61, book value per share A$0.71, current ratio proxy strong, and research spend running high at R&D to revenue 84.34%, which supports product development but pressures margins.

AYA.AX stock technicals and trading setup

Short-term technicals show RSI 38.32 and CCI -121.68, suggesting oversold conditions while 50-day average A$3.88 sits above current price. Traders should note a 200-day average A$2.56, Bollinger middle A$3.24, and relative volume 0.58, indicating lower trading intensity versus recent weeks.

Meyka AI rates AYA.AX with a score out of 100 and forecast

Meyka AI rates AYA.AX with a score out of 100: 63.50 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of A$7.41, a quarterly target of A$4.36, and a monthly projection of A$3.05; these are model-based projections and not guarantees.

AYA.AX stock risks, opportunities and analyst context

Upside depends on commercial uptake of Salix, reimbursement wins and tighter operating leverage; downside risks include negative EPS, thin revenue per share and high R&D spend. Third-party company ratings note mixed signals on valuation metrics and recommend caution, which should be read alongside our AI-driven forecasts.

Final Thoughts

Key takeaways on AYA.AX stock: Artrya trades at A$3.10 pre-market on 06 Mar 2026 with clear near-term volatility and longer-term optionality from its AI diagnostics platform. Financials show negative EPS -0.17 and PE -17.76, but solid cash per share A$0.61 and low balance sheet leverage support further product roll-out. Meyka AI’s forecast model projects a yearly price of A$7.41, implying an upside of 138.97% from today’s price; quarterly guidance at A$4.36 implies 40.65% upside while the monthly model at A$3.05 sits marginally below current levels. These scenarios highlight a classic AI-stocks trade-off: high execution risk against large addressable market gains. We link recent company financial summaries from Reuters and StockAnalysis for background and track adoption signals via Artrya’s commercial updates and ASX filings. Meyka AI is an AI-powered market analysis platform and these forecasts are model-based projections and not investment advice. For active traders we recommend monitoring volume spikes, successive revenue announcements, and quarterly uptake metrics as immediate catalysts. For investors focused on AI healthcare exposure, AYA.AX stock merits a watchful HOLD until clearer commercial traction appears.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.